Uncategorized
Oral Antiviral Blocks Measles-Like Virus Transmission in Ferrets
Oral Antiviral Blocks Measles-Like Virus Transmission in Ferrets
This year, the United States has recorded the highest number of measles cases since 2000, the year that the disease was declared eliminated from the country. As of mid-July, 2,260 measles cases were reported—just 29 cases less than the entire year of 2025. And outbreaks are widespread, with 34 new outbreaks reported in 2026.
The reason for this surge in cases is waning vaccination rates across the country. Given that, the production of new antivirals is an urgent matter.

Now, the new oral antiviral drug candidate GHP-88310 has shown promising results in a ferret model of infection. When administered before or after direct contact or airborne exposure to canine distemper virus (which causes measles-like disease in ferrets) GHP-88310 blocked transmission of the virus and reduced clinical symptoms in ferrets.
“We were very excited to see that GHP-88310 given by mouth completely prevented airborne transmission in our ferret model of measles,” said Carolin Lieber, PhD, a postdoctoral fellow in the Plemper lab at Georgia State University. “This finding is unprecedented for a viral polymerase inhibitor and demonstrates the extraordinary antiviral potency of this drug.”
This research is published in Nature Microbiology in the paper, “Antiviral GHP-88310 blocks contact-mediated and airborne transmission in a ferret model of measles-like disease.”
“Silencing measles outbreaks quickly is essential to reestablish control over the virus,” said Richard Plemper, PhD, professor and director of the Center for Translational Antiviral Research (CTAR) at Georgia State University. “This study follows our recent development of the drug candidate GHP-88310. It demonstrates that the drug is suitable to augment traditional ring vaccination against measles.”
GHP-88310 (described earlier this year in Science Advances) is known to be an orally efficacious broad-spectrum orthoparamyxovirus polymerase inhibitor. But its effect on viral transmission has remained unclear. This study explored whether prophylactic administration of GHP-88310 prevents virus transmission through close contact or through the air. The results demonstrate that GHP-88310 efficiently blocks both forms of viral spread. In addition, the study showed that treatment of infected animals shortened the time period in which infected animals could transmit the virus.
To explore relevant conditions of viral transmission, the researchers established both direct-contact and airborne canine distemper virus transmission models to examine pharmacological suppression of virus spread. The transmission systems allowed them to pair infected and uninfected animals in direct physical contact or shared airspace, each under controlled environmental parameters.
“We designed the study to recapitulate viral spread between people with direct contact, for instance in a household, and between more distant social contacts, for example in classrooms or other indoor settings that bring people into proximity without direct interaction,” said Plemper.
The results showed that pre- and post-exposure prophylactic GHP-88310, given twice daily to air contacts, prevented transmission. The authors note that once-daily prophylactic administration mediated complete survival with all air contacts undergoing seroconversion. In addition, they note that therapeutic treatment of air contacts mitigated clinical signs, and animals survived, whereas all vehicle-treated air contacts succumbed. In addition, therapeutic treatment of infected source animals shortened the contagious phase by five days.
“In addition to this prophylactic benefit, GHP-88310 used therapeutically shortened the duration of disease in our model,” noted Plemper. “If equally applicable to human hosts, it may shorten the severe social and economic burden of prolonged quarantine of patients and further aid outbreak management.” The investigators are now readying GHP-88310 for formal clinical testing.
The post Oral Antiviral Blocks Measles-Like Virus Transmission in Ferrets appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read